Editorial: Emerging talents in alloimmunity and transplantation: 2022

Guido Moll; Wai H Lim; Olaf Penack

doi:10.3389/fimmu.2024.1393026

Editorial: Emerging talents in alloimmunity and transplantation: 2022

Front Immunol. 2024 Mar 15:15:1393026. doi: 10.3389/fimmu.2024.1393026. eCollection 2024.

Authors

Guido Moll^{1

2}, Wai H Lim^{3

4

5}, Olaf Penack^{6

7}

Affiliations

¹ BIH Center for Regenerative Therapies (BCRT) and Berlin-Brandenburg School for Regenerative Therapies (BSRT), Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany.
² Department of Nephrology and Internal Intensive Care Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany.
³ Department of Renal Medicine, Sir Charles Gairdner Hospital, Perth, WA, Australia.
⁴ School of Medical and Health Sciences, Edith Cowan University, Perth, WA, Australia.
⁵ Medical School, University of Western Australia, Perth, WA, Australia.
⁶ Department of Hematology, Oncology and Tumorimmunology, Charité Universitätsmedizin Berlin, Berlin, Germany.
⁷ BIH Biomedical Innovation Academy, Charité Universitätsmedizin Berlin, Berlin, Germany.

No abstract available

Keywords: alloimmunity; cell therapy; human leukocyte antigen (HLA); immunomodulation; immunosuppression; inflammation; rejection; transplantation.

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Histocompatibility*
Transplantation Immunology*

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. GM was supported by grants from the German Federal Ministry of Education and Research (BMBF) and the German Research Foundation (DFG: EXPAND-PD project #CA2816/1) and through the BIH Center for Regenerative Therapies (BCRT) and the Berlin-Brandenburg School for Regenerative Therapies (BSRT: GSC203), respectively, and in part by the European Union’s Horizon 2020 Research and Innovation Program and the grant agreements No 733006 (PACE), 779293 (HIPGEN), 754995 (EU-TRAIN), and 101095635 (PROTO).